Key result
Baxdrostat lowers office systolic blood pressure by ~9 mmHg compared with placebo.
Why the study?
Baxdrostat is a selective aldosterone synthase inhibitor developed for uncontrolled and resistant hypertension, warranting a pooled evaluation of its efficacy and safety across randomized trials.
Does baxdrostat reduce blood pressure safely in adults with uncontrolled or resistant hypertension compared with placebo?
Meta-Analysis (n=1,285)
Does baxdrostat reduce blood pressure safely in adults with uncontrolled or resistant hypertension compared with placebo?
Baxdrostat provides significant short-term reductions in office and 24-hour ambulatory blood pressure in resistant or uncontrolled hypertension, though with an increased risk of hyperkalemia requiring monitoring.
Answers are grounded in this paper and cite their sources.
Baxdrostat reduces office SBP in resistant hypertension; confirms efficacy of aldosterone synthase inhibition in meta-analysis.
Baxdrostat is a selective aldosterone synthase inhibitor developed for uncontrolled and resistant hypertension. This systematic review and meta-analysis evaluated the efficacy and safety of baxdrostat in randomized trials. The review was reported in accordance with PRISMA guidance. PubMed, Scopus, Web of Science, and the Cochrane Library were searched through March 2026 for randomized controlled trials comparing baxdrostat with placebo in adults with uncontrolled or resistant hypertension. Quantitative synthesis used a random-effects model, and certainty of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework. Three RCTs comprising 1,285 participants in the treated/modified intention-to-treat populations were included. Baxdrostat reduced office systolic blood pressure (MD = -9.06 mmHg; 95% CI: -11.03 to -7.09; P < 0.01), office diastolic blood pressure (MD = -3.62 mmHg; 95% CI: -4.86 to -2.38; P < 0.0001), and 24-hour ambulatory systolic blood pressure (MD = -14.27 mmHg; 95% CI: -17.13 to -11.41; P < 0.01). Any adverse events occurred in 46.5% of baxdrostat-treated versus 40.0% of placebo participants (RR = 1.17; 95% CI: 1.02 to 1.33), while hyperkalemia occurred in 4.9% versus 0.2% (RR = 9.39; 95% CI: 2.23 to 39.57). Baxdrostat was associated with short-term reductions in office and ambulatory blood pressure in the included randomized trials. Hyperkalemia and changes in renal function remain clinically relevant safety considerations, and longer-term studies are needed to define its durability, renal safety, and effects on cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Al-Zahrani et al. (2026) conducted a meta-analysis in Uncontrolled or resistant hypertension (n=1,285). Baxdrostat vs. Placebo was evaluated on Office systolic blood pressure (MD -9.06 mmHg, 95% CI -11.03 to -7.09, p=<0.01). Baxdrostat reduced office systolic blood pressure compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: